Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of TOR-582, a Topical Sirolimus-based Treatment for Epistaxis in Adults With Hereditary Hemorrhagic Telangiectasia

NCT07667413 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT07667413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07667413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of TOR-582, a Topical Sirolimus-based Treatment for Epistaxis in Adults With Hereditary Hemorrhagic Telangiectasia
Lead sponsor
Columbia University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2027
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epistaxis, hereditary hemorrhagic telangiectasia (hht)